Ubiquitin proteasome inhibition and cancer therapy

Surgery

Volumn 131, Issue 6, 2002, Pages 595-600

  Shah, Shimul A ^a,b   Potter, Michael W ^a,b   Callery, Mark P ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

APOPTOSIS; CANCER THERAPY; CELL CYCLE; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; TRANSCRIPTION REGULATION;

EID: 0036087686     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2002.121890     Document Type: Article

References (19)

1. Proteasome inhibitors: Valuable new tools for cell biologists
2. The ubiquitin-proteasome proteolytic pathway
3. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
4. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
5. The proteasome inhibitor PS-341 in cancer therapy
6. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
7. Proteasome inhibitors: A novel class of potent and effective antitumor agents
8. 26S proteasome inhibition induces apoptosis and limits growth in human pancreatic cancer
9. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
10. In vivo ubiquination and proteasome-mediated degradation of p53
11. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
12. WAFI expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer
13. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
14. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B
15. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B
16. NF-B antiapoptosis: Induction of TRAF1, TRAF2, c-IAP1 and c-IAP2 to suppress caspase-8 activation
17. NF-kappa B activation by campothecin
18. PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies
19. Phase 1 trial of the proteasome inhibitor PS-341 in advanced malignancy